ACADIA Pharmaceuticals

$48.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.66 (+3.51%) Today
-$0.96 (-1.96%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ACAD and other stocks, options, and ETFs commission-free!

About ACAD

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA. The listed name for ACAD is ACADIA Pharmaceuticals Inc. Common Stock.

CEO
Stephen R. Davis
Employees
503
Headquarters
San Diego, California
Founded
1993
Market Cap
8.19B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
848.59K
High Today
$49.37
Low Today
$47.13
Open Price
$47.34
Volume
992.87K
52 Week High
$58.72
52 Week Low
$30.02

ACAD News

BenzingaFeb 25

ROCE Insights For ACADIA Pharmaceuticals

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported Q4 sales of $121.01 million. Earnings fell to a loss of $67.16 million, resulting in a 21.81% decrease from last q
BenzingaFeb 23

A Preview Of ACADIA Pharmaceuticals's Earnings

On Wednesday, February 24, ACADIA Pharmaceuticals (NASDAQ:ACAD) will release its latest earnings report. Check out Benzinga's preview to understand the implicat

ACAD Earnings

-$0.57
-$0.47
-$0.37
-$0.27
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.47 per share
Actual
-$0.42 per share
Replay Earnings Call

You May Also Like

LL
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure